Antiflu Kids Powder for Oral Solution, 12 g each, No. 5 per package
Ingredients
Active ingredients: acetaminophen, ascorbic acid, chlorpheniramine maleate;
1 packet contains 160 mg of acetaminophen, 50 mg of ascorbic acid, and 1 mg of chlorpheniramine maleate;
inactive ingredients: anhydrous citric acid, silicon dioxide, colloidal anhydrous silicon dioxide, sodium citrate dihydrate, corn starch, confectioners’ sugar, sucrose, titanium dioxide (E 171), calcium phosphate, Special Red AC (E 129), raspberry flavoring.
Dosage Form
Powder for oral solution.
Main physical and chemical properties: a free-flowing white or nearly white powder containing crystalline particles, with a slight raspberry odor.
Pharmacotherapeutic group
Analgesics and antipyretics. ATC code N02B E51.
Pharmacological properties
Pharmacodynamics.
Acetaminophen has analgesic, antipyretic, and mild anti-inflammatory effects. Its mechanism of action involves the inhibition of prostaglandin synthesis and an effect on the thermoregulatory center in the hypothalamus.
Ascorbic acid (vitamin C), as a key component of the antioxidant and immune defense systems, enhances the body’s adaptive capacity and increases its resistance to infections. It plays an active role in regulating redox processes, carbohydrate metabolism, the synthesis of steroid hormones and catecholamines, and blood clotting. It enhances collagen synthesis, stimulates regenerative processes, and normalizes capillary permeability.
Chlorpheniramine maleate is an antihistamine of the alkylamine class and an H1-histamine receptor blocker. It has an antiallergic effect, relieving rhinorrhea, lacrimation, and itching in the eyes and nose. The therapeutic effect develops within one hour after oral administration and lasts for 24 hours.
The components of the drug are metabolized independently of one another.
Pharmacokinetics.
After oral administration, acetaminophen is rapidly absorbed, primarily in the upper gastrointestinal tract. It is rapidly distributed throughout the tissues. Protein binding is less than 10%. Acetaminophen is metabolized primarily in the liver: most of it is conjugated with glucuronic acid, and a smaller portion with sulfuric acid. The half-life of acetaminophen is 2–2.5 hours. It is prolonged in individuals with liver disease.
Acetaminophen is excreted in the urine (85% of a single dose of acetaminophen is excreted within 24 hours). Excretion is significantly impaired in cases of impaired renal excretory function, which may lead to the accumulation of acetaminophen and its metabolites in the body. Ascorbic acid is actively absorbed in the small intestine. After oral administration, peak plasma concentrations are reached within 4 hours. From the blood plasma, it readily penetrates into leukocytes, platelets, and virtually all tissues. It undergoes biotransformation in the liver and is excreted in the urine: partly unchanged and partly as metabolites.
Chlorpheniramine maleate is metabolized in the liver. The half-life is 8 hours. Chlorpheniramine maleate and its metabolites are excreted in the urine.
Indications
Prescribed for children aged 2 to 12 years for influenza, acute respiratory viral infections, and the common cold to reduce fever, relieve headaches, muscle and joint pain, rhinorrhea, sneezing, watery eyes, and other symptoms of inflammation of the mucous membranes of the upper respiratory tract and paranasal sinuses.
Contraindications
Hypersensitivity to any of the drug’s ingredients or to other antihistamines; severe liver dysfunction (> 9 points on the Child-Pugh scale) and/or kidney dysfunction; alcoholism; congenital glucose-6-phosphate dehydrogenase deficiency; congenital hyperbilirubinemia (including Gilbert’s syndrome); hematopoietic disorders, blood diseases, severe leukopenia, anemia, predisposition to thrombosis; severe cardiac conduction disorders, decompensated heart failure; bladder neck obstruction; pyloroduodenal obstruction; thrombosis, thrombophlebitis; severe forms of diabetes mellitus; angle-closure glaucoma; active gastric and duodenal ulcers; children under 2 years of age.
Do not use concomitantly with monoamine oxidase (MAO) inhibitors or within 2 weeks after discontinuing MAO inhibitors. MAO inhibitors should not be used concomitantly with antihistamines due to the potential for additive central nervous system (CNS) depression. They may prolong and intensify the anticholinergic effects of antihistamines.
Drug Interactions and Other Interactions
When used concomitantly with acetaminophen, the following interactions are possible:
- slowed elimination of antibiotics from the body;
- anticonvulsants (including phenytoin, barbiturates, and carbamazepine), rifampin, and alcohol increase the hepatotoxicity and nephrotoxicity of acetaminophen;
- barbiturates reduce the antipyretic effect of acetaminophen;
- tetracycline increases the risk of acetaminophen-induced anemia and methemoglobinemia;
- when paracetamol is used concomitantly with hepatotoxic agents, the toxic effect of these drugs on the liver is increased; do not use concomitantly with alcohol;
- Acetaminophen reduces the effectiveness of diuretics;
- Concomitant use of high doses of acetaminophen with isoniazid or rifampicin increases the risk of hepatotoxic syndrome;
- enhanced effect of indirect anticoagulants with an increased risk of bleeding;
- The rate of acetaminophen absorption increases with the use of metoclopramide and domperidone and decreases with the use of cholestyramine;
- Concomitant long-term use with coumarin derivatives (e.g., warfarin) may potentiate their effects, increasing the risk of bleeding; Patients taking oral anticoagulants should consult a doctor; blood clotting parameters should be monitored;
- Taking paracetamol (acetaminophen) may affect blood glucose test results measured using the glucose oxidase-peroxidase method, leading to abnormally high concentrations;
- Paracetamol may affect blood urea levels when measured using the phosphotungstic acid method;
- Tropisetron and granisetron, type 3 5-hydroxytryptamine antagonists, may completely block the analgesic effect of paracetamol due to a pharmacodynamic interaction;
- Concomitant use of acetaminophen and zidovudine increases the risk of a decrease in white blood cell count (neutropenia); therefore, these medications should not be used together unless otherwise recommended by a doctor;
- The absorption of ascorbic acid is reduced when taken concurrently with oral contraceptives, fruit or vegetable juices, or alkaline beverages;
- When taken orally, ascorbic acid increases the absorption of penicillin, tetracycline, and iron, and raises ethinyl estradiol levels; reduces the effectiveness of heparin and indirect anticoagulants, and increases the risk of crystalluria during treatment with salicylates;
- concomitant use of vitamin C and deferoxamine increases the tissue toxicity of iron, especially in the heart muscle, which may lead to cardiovascular decompensation; vitamin C should be taken only 2 hours after an injection of deferoxamine;
- High doses of the drug reduce the effectiveness of tricyclic antidepressants and phenothiazine-derived neuroleptics, decrease tubular reabsorption of amphetamine, and impair renal excretion of mexiletine;
- ascorbic acid increases the total clearance of ethyl alcohol;
- quinoline derivatives, calcium chloride, salicylates, and corticosteroids, when used long-term, reduce the body’s stores of ascorbic acid.
Concomitant use of Antiflu® Kids with medications such as hypnotics, sedatives, neuroleptics, and tranquilizers may significantly increase the sedative effect of chlorpheniramine maleate.
Chlorpheniramine potentiates the anticholinergic effects of atropine, antispasmodics, tricyclic antidepressants, and antiparkinsonian drugs. Monoamine oxidase (MAO) inhibitors should not be prescribed in combination with antihistamines due to the potential additive depressant effect on the central nervous system. They may prolong and intensify the anticholinergic effects of antihistamines.
Special Considerations for Use
Concomitant use with other medications intended for the symptomatic treatment of the common cold and flu, as well as medications containing acetaminophen, should be avoided. Do not exceed the specified dose or duration of treatment. Concomitant use with other medications containing acetaminophen may lead to an overdose. An acetaminophen overdose can cause liver failure, which may result in the need for a liver transplant or death.
In patients with reduced glutathione levels—for example, in cases of severe infections such as sepsis—the risk of metabolic acidosis increases when taking acetaminophen. Symptoms of metabolic acidosis include deep, rapid, or labored breathing, nausea, vomiting, and loss of appetite. Seek immediate medical attention if these symptoms occur.
If symptoms persist, consult a doctor.
Long-term use of high doses may lead to liver and kidney damage; the use of multiple medications simultaneously, alcoholism, alcoholic liver disease, sepsis, or diabetes may increase the risk of paracetamol (acetaminophen) hepatotoxicity even at therapeutic doses.
It should be noted that patients with liver disease are at increased risk of paracetamol-induced hepatotoxicity. Consult a physician regarding the use of this medication in patients with mild to moderate renal or hepatic impairment.
This medication is not recommended for use in combination with sedatives or hypnotics.
Consult a doctor before using this medication if the patient is taking warfarin or similar medications with anticoagulant effects.
Paracetamol may affect the results of laboratory tests for blood glucose and uric acid levels.
A doctor should prescribe this medication only after assessing the risk-benefit ratio in the following cases: severe hypertension, epilepsy, glaucoma, oxalaturia, urinary disorders, urinary retention, enlarged prostate, asthma, respiratory distress due to bronchitis, croup, or pneumonia, thyrotoxicosis, or glutathione deficiency.
The recommended dose and duration of treatment should not be exceeded. If, on the recommendation of a physician, the drug is used for a prolonged period, liver function and peripheral blood counts must be monitored.
Very rare cases of severe skin reactions have been reported. If skin redness, a rash, blisters, or peeling occur, stop taking acetaminophen and seek medical attention immediately.
1 packet (1 dose) contains 11.6 g of sugar, which should be taken into account by patients with diabetes and those on a low-sugar diet. Use with caution in patients with diabetes. Taking this medication with alkaline beverages reduces the absorption of ascorbic acid; therefore, do not take the powder with alkaline mineral water. Absorption of ascorbic acid may also be impaired in cases of intestinal dyskinesia, enteritis, and achilia.
Do not use this medication if you have fructose intolerance, glucose-galactose malabsorption syndrome, or sucrase-isomaltase deficiency, due to its sucrose (sugar) content. If you have been diagnosed with an intolerance to certain sugars, consult your doctor before taking this medication.
If you develop a high body temperature or a prolonged fever lasting more than 3 days while taking this medication, or if signs of a superinfection appear, consult a doctor.
Ascorbic acid may alter the results of laboratory tests (glucose, blood bilirubin, transaminase activity).
Do not take this medication with other products for the symptomatic treatment of colds and flu that contain acetaminophen or antihistamines. If symptoms do not go away, consult a doctor. If headaches become persistent, you should also consult a doctor.
Chlorpheniramine maleate may mask the symptoms of hypersensitivity reactions and affect the results of skin tests. Therefore, use of this medication should be discontinued several days before undergoing these procedures.
Use during pregnancy or breastfeeding.
Do not use.
Effect on reaction time when driving or operating machinery.
Due to the possibility of drowsiness following the use of chlorpheniramine maleate, children should be prevented from engaging in activities requiring increased concentration for 4 hours after taking the medication.
Dosage and Administration
Administer orally, regardless of meals, after first dissolving the contents of the packet in a glass of hot (not boiling) water. The recommended amount of water for dissolving the powder is usually the volume that a child drinks in a single dose (100–200 mL). The single dose for children aged 2–5 years is the contents of 1 packet; for children aged 6–12 years, it is the contents of 2 packets. If necessary, repeat the dose every 4–6 hours, but do not exceed 4 packets per day. The maximum duration of use without consulting a doctor is 3 days. Further use is possible only under a doctor’s supervision.
Children.
Do not use in children under 2 years of age. Consult a doctor before administering the medication to children aged 2–5 years.
The maximum dose for children is up to 100 mg/kg per day or 4,000 mg per day.
Overdose
No cases of Antiflu® Kids overdose have been reported. Symptoms of overdose with this medication consist of signs of intoxication from individual active ingredients.
In patients with risk factors, therapeutic doses of acetaminophen may cause symptoms of overdose when used concomitantly with certain medications (see the section “Interactions with Other Medications and Other Types of Interactions”) and in conditions that increase oxidative stress and deplete glutathione stores in the liver (prolonged fasting, sepsis, diabetes mellitus).
The most significant effects of acute intoxication are hepatotoxicity—hepatocellular damage associated with the binding of active paracetamol metabolites to liver cell proteins. At therapeutic doses, these metabolites bind to glutathione and form nontoxic conjugates. In the event of a massive overdose, the liver’s reserves of SH-group donors (which contribute to glutathione formation) are depleted. This leads to the accumulation of toxic metabolites and hepatocyte necrosis, followed by impaired liver function that progresses to hepatic coma.
Symptoms of an overdose caused by acetaminophen within the first 24 hours include pallor, nausea, vomiting, anorexia, general weakness, and abdominal pain. The patient’s condition may improve within 24–48 hours, although symptoms may persist.
When large doses are taken, psychomotor agitation or central nervous system depression, increased sweating, dizziness, and sleep disturbances may also occur.
Occasionally, nephrotoxicity has been observed in the urinary system, including renal colic, interstitial nephritis, and acute renal failure with acute tubular necrosis, which may manifest as severe pain in the lumbar region, hematuria, proteinuria, and may develop even in the absence of severe liver damage. In severe cases, liver damage (hepatocellular necrosis) and impaired liver function may occur, which can progress to hepatic encephalopathy, hepatic coma, cerebral edema, and result in death. Clinical signs of liver damage may not appear for 12–48 hours after an overdose. The liver rapidly enlarges. Glucose metabolism disorders, hypokalemia, and metabolic acidosis (including lactic acidosis) may occur, along with elevated liver transaminase levels, elevated bilirubin levels and an increased prothrombin index, and hemorrhages. Urine output decreases, and mild azotemia may be observed. In children, liver damage may develop after administration of more than 150 mg/kg of body weight. Common clinical manifestations, which appear 3–5 days after exposure, include jaundice, fever, hemorrhagic diathesis, hypoglycemia, a liver-like odor on the breath, and liver failure.
Taking 5 g or more of acetaminophen may lead to liver damage in patients with risk factors (long-term treatment with carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St. John’s wort, or other medications that induce liver enzymes; regular consumption of excessive amounts of ethanol; glutathione deficiency (gastrointestinal disorders, cystic fibrosis, HIV infection, starvation, cachexia)).
Arrhythmia (abnormal heart rhythm) and pancreatitis have also been reported. When taken in high doses, central nervous system effects may include disorientation.
With prolonged use at high doses, aplastic anemia, pancytopenia, agranulocytosis, neutropenia, leukopenia, and thrombocytopenia may occur.
Chronic intoxication involves various forms of liver damage. Data on the chronic toxicity of acetaminophen, particularly its nephrotoxicity, are conflicting. During long-term use, attention should be paid to peripheral blood tests.
In case of an overdose of chlorpheniramine maleate, atropine-like symptoms may occur: mydriasis, photophobia, dry skin and mucous membranes, elevated body temperature (hyperpyrexia), tachycardia, intestinal atony, and facial flushing. Typically, symptoms of central nervous system excitation are observed first (psychomotor agitation, psychosis, hallucinations, tremor, impaired motor coordination, hyperreflexia, convulsions), followed by depression, drowsiness, altered consciousness, accompanied by respiratory disturbances and cardiovascular dysfunction (cardiac arrhythmias, extrasystoles, decreased heart rate, decreased blood pressure, potentially leading to circulatory failure and death).
Emergency care for antihistamine poisoning consists of symptomatic and supportive treatment, including mechanical ventilation.
Emergency Care. The patient should be transported immediately to a hospital’s intensive care unit, even if there are no early symptoms of overdose. Continuous monitoring of vital signs, laboratory parameters, and cardiovascular status should be ensured. Symptoms may be limited to nausea and vomiting or may not reflect the severity of the overdose or the risk of organ damage. Treatment with activated charcoal should be considered if an excessive dose of acetaminophen was ingested within 1 hour. Plasma paracetamol concentrations should be measured 4 hours or more after ingestion (earlier measurements are unreliable). Gastric lavage should be performed within 6 hours of a suspected acetaminophen overdose. Hemodialysis and hemoperfusion facilitate the elimination of the substance. Cytotoxic effects can be reduced by administering SH-group donors (oral methionine or intravenous cysteamine or N-acetylcysteine) within 10 hours of the overdose, as they bind to active metabolites and promote detoxification. N-acetylcysteine may be effective up to 48 hours after poisoning. The effectiveness of the antidote decreases sharply after this period.
Symptoms of ascorbic acid overdose. There is no evidence that this medication can lead to an overdose when used as recommended. A single administration of excessive doses of the drug may cause nausea, vomiting, bloating, and abdominal pain, itching, skin rash, and increased irritability. With prolonged use in high doses, suppression of the pancreatic islet cells may occur (pancreatic function must be monitored), as well as the development of cystitis and accelerated formation of stones (urates, oxalates). The effects of ascorbic acid overdose may be classified as severe hepatotoxicity resulting from paracetamol overdose.
High doses of ascorbic acid (more than 3,000 mg) may cause temporary osmotic diarrhea and gastrointestinal disturbances.
Treatment: Perform gastric lavage; administer an alkaline drink, activated charcoal, or other absorbents to the patient.
Side Effects
In most cases, the drug is well tolerated.
The following adverse effects may occur:
- blood system: anemia, sulfhemoglobinemia, and methemoglobinemia (cyanosis, dyspnea, chest pain), hemolytic anemia (if the patient has glucose-6-phosphate dehydrogenase deficiency), thrombocytopenia, thrombocytosis, hyperprothrombinemia, erythrocytopenia, neutrophilic leukocytosis, agranulocytosis, thrombocytopenic purpura, leukopenia, bruising, or bleeding;
- respiratory system: bronchospasm in patients sensitive to acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs;
- Gastrointestinal system: dyspepsia, nausea, vomiting, dry mouth, epigastric discomfort and pain, hypersalivation, decreased appetite, heartburn, diarrhea;
- Endocrine system: hypoglycemia, up to and including hypoglycemic coma; damage to the pancreatic islets (hyperglycemia, glucosuria), and impaired glycogen synthesis, up to the development of diabetes mellitus;
- hepatobiliary system: liver dysfunction, elevated liver enzyme levels, usually without the development of jaundice, hepatonecrosis (dose-dependent effect);
- Immune system: hypersensitivity reactions (including allergic reactions), anaphylactic reactions, and anaphylactic shock;
- nervous system: headache, dizziness, psychomotor agitation and disorientation, anxiety, fear, sleep disturbances, drowsiness, insomnia, confusion, coma, seizures, dyskinesia, behavioral changes;
- cardiovascular system: tachycardia, reflex bradycardia, shortness of breath, chest pain, increased blood pressure, arrhythmia, myocardial dystrophy (a dose-dependent effect with long-term use);
- Urinary system: renal colic and interstitial nephritis, urinary retention and difficulty urinating, aseptic pyuria, with long-term use at high doses—damage to the glomerular apparatus of the kidneys, crystalluria, formation of urate, cystine, and/or oxalate stones in the kidneys and urinary tract;
- Ocular side effects: accommodation disorders, dry eyes, mydriasis, visual disturbances, increased intraocular pressure;
- Metabolic disorders: disturbances in zinc and copper metabolism, hypokalemia;
- skin and subcutaneous tissue disorders: pruritus, rash on the skin and mucous membranes (usually generalized rash, erythema, urticaria), allergic and angioedema, acute generalized exanthematous pustulosis, localized drug-induced dermatitis, erythema multiforme (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome), including fatal cases.
Shelf life
3 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 ºC.
Keep out of reach of children.
Packaging
Powder, dosed in 12 g portions, in paper pouches laminated with aluminum foil and polyethylene. 5 pouches per cardboard box.
Dispensing Category
Over-the-counter.
Manufacturer
Contract Pharmacal Corporation.
Similar products
Products from the same category











